Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Picolinic Acid SCHEMBL2291560 | 0.85 | LMNA (0.67) | CES2CES1LMNAL3MBTL1NAPRT | |
| 2-Picolinic Acid SCHEMBL27223671 | 0.85 | LMNA (0.67) | CES2CES1LMNAL3MBTL1NAPRT | |
| Pyrrole SCHEMBL1194080 | 0.83 | CES2 (0.53) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL4914089 | 0.82 | CES2 (0.67) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL1505348 | 0.82 | — | — | |
| SCHEMBL61183 | 0.82 | — | — | |
| SCHEMBL9094627 | 0.80 | CES2 (0.64) | CES2CES1LMNAL3MBTL1NAPRT | |
| Hydrochloric Acid SCHEMBL1704886 | 0.80 | CES2 (0.64) | CES2CES1LMNAL3MBTL1NAPRT | |
| Ammonia Solution, Strong SCHEMBL902138 | 0.80 | CES2 (0.64) | CES2CES1LMNAL3MBTL1NAPRT | |
| Hydrochloric Acid SCHEMBL17493405 | 0.80 | CES2 (0.64) | CES2CES1LMNAL3MBTL1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107880022-A | A kind of compound of chirality amide-type containing Imidazopyridine and its preparation method and application | 浙江大学 | 2018-04-06 | — | — | CN | claimed |
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | claimed |
| US-20260007650-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY FUNGUS BY ADMINISTRATION OF TAFENOQUINE | 60 DEGREES PHARMACEUTICALS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12383546-B2 | Methods for the treatment and prevention of lung infections caused by fungus by administration of tafenoquine | 60 DEGREES PHARMACEUTICALS LLC (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240226087-A9 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE | 60 DEGREES PHARMACEUTICALS LLC (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240165099-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF DISEASES OR INFECTIONS WITH MCP-1 INVOLVEMENT BY ADMINISTRATION OF TAFENOQUINE | 60 DEGREES PHARMACEUTICALS LLC (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240131019-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE | 60 DEGREES PHARMACEUTICALS LLC (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024073077-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF DISEASES OR INFECTIONS WITH MCP-1 INVOLVEMENT BY ADMINISTRATION OF TAFENOQUINE | 60 DEGREES PHARMACEUTICALS LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11633391-B2 | Methods for the treatment and prevention of lung infections caused by gram-positive bacteria, fungus, or virus by administration of tafenoquine | 60 DEGREES PHARMACEUTICALS LLC (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2008005908-A2 | PYRIDOIMIDAZOLE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | WO | disclosed |
| EP-1684736-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | Kudos Pharmaceuticals Limited (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
| WO-2005053662-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
| EP-0245637-B1 | 4,5,6,7-Tetrahydro-1H-imidazo[4,5-c]pyridine derivatives and analogs having antihypertensive activity | WARNER-LAMBERT COMPANY (US) | 1991-10-16 | — | — | EP | disclosed |
| US-4816463-A | HYPERTENSION | WARNER-LAMBERT COMPANY (US) | 1989-03-28 | — | — | US | disclosed |
| US-4812462-A | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity | WARNER-LAMBERT COMPANY (US) | 1989-03-14 | — | — | US | disclosed |
| EP-0245637-A1 | 4,5,6,7-Tetrahydro-1H-imidazo[4,5-c]pyridine derivatives and analogs having antihypertensive activity | WARNER-LAMBERT COMPANY (US) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383546-B2 | Methods for the treatment and prevention of lung infections caused by fungus by administration of tafenoquine | MTAP, ASAH2, TPMT | CES2 1122/4885CES1 191/4885LMNA 1923/4885 |
| US-20260007650-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY FUNGUS BY ADMINISTRATION OF TAFENOQUINE | SLC11A2, RPTOR, ABCC1 | CES2 1166/4885CES1 368/4885LMNA 1627/4885 |
| US-11633391-B2 | Methods for the treatment and prevention of lung infections caused by gram-positive bacteria, fungus, or virus by administration of tafenoquine | ACE2, ACE, SARS1 | CES2 1228/4885CES1 405/4885LMNA 2758/4885 |
| US-20240226087-A9 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE | ACE2, ACE, SARS1 | CES2 1228/4885CES1 405/4885LMNA 2758/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | CES2 4517/4885CES1 3173/4885LMNA 1899/4885 |
| US-20240131019-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE | ACE2, ACE, SARS1 | CES2 1228/4885CES1 405/4885LMNA 2758/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | CES2 4584/4885CES1 3373/4885LMNA 1960/4885 |
| US-20240165099-A1 | METHODS FOR THE TREATMENT AND PREVENTION OF DISEASES OR INFECTIONS WITH MCP-1 INVOLVEMENT BY ADMINISTRATION OF TAFENOQUINE | CCL11, CCL5, CCL2 | CES2 1074/4885CES1 157/4885LMNA 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.